Key result
YM337 significantly reduced the ratio of infarcted area to the whole cerebrum compared to saline (5.5% low dose, 5.7% high dose vs 12.3%) in monkeys with focal cerebral ischemia.
Why the study?
Does YM337 reduce infarct area and neurologic deficits in monkeys with thrombotic distal middle cerebral artery occlusions?
Population
Monkeys with thrombotic distal middle cerebral artery occlusions induced by a photochemical reaction between…
Comparison
YM337 intravenously injected 30 min after rose… vs Saline control group and sodium ozagrel group
Design
Preclinical
Follow-up
24 hours
Authors
Loading...
Supports glycoprotein IIb/IIIa blockade in primate cerebral ischemia models; leaves open translation to human stroke therapy.
Does YM337 reduce infarct area and neurologic deficits in monkeys with thrombotic distal middle cerebral artery occlusions?
Absolute Event Rate: 5.5% vs 12.3%
Blockade of glycoprotein IIb/IIIa with YM337 lessens infarct size and neurologic deficits in a primate model of cerebral artery thrombosis.
Kaku et al. (1999) studied focal cerebral ischemia. YM337 vs. saline and sodium ozagrel was evaluated on ratio of infarcted area to the whole area of the cerebrum. YM337 significantly reduced the ratio of infarcted area to the whole cerebrum compared to saline (5.5% low dose, 5.7% high dose vs 12.3%) in monkeys with focal cerebral ischemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: